Advances and perspectives in animal models of human hepatitis A virus

Abstract

Hepatitis A virus (HAV) is an important pathogen that has continuously posed a threat to global public health for over 5000 years. The development of accessible and reliable small animal models, especially murine models, is essential for elucidating HAV pathogenesis and advancing preventive and therapeutic strategies. The first mouse model for HAV infection was established using human-liver chimeric mice, which supported robust viral replication and high viral loads. Later, an Ifnar1^−/− mice model was established with a specific mouse-adapted strain, recapitulating key clinical features of human hepatitis A. Recently, to overcome limitations associated with the difficulty in obtaining and amplifying stocks of HAV for animal models, our laboratory established a novel hepatitis A mouse model using lipid nanoparticle-encapsulated viral genomic RNA (LNP-vRNA). This approach provides a new strategy for modeling infections of hard-to-culture RNA viruses. In this review, we systematically summarize and compare these mouse models, respectively highlighting their advantages and limitations, and offer guidance for their application in future HAV research.

Keywords

animal models / hepatitis A virus / LNP-vRNA based mouse model

References

[1] Stanley M, Lemon J, Ott J, et al. Type a viral hepatitis: a summary and update on the molecular virology, epidemiology, pathogenesis and prevention. J Hepatol. 2018; 68: 167-184.

[2] WHO. WHO position paper on hepatitis A vaccines. Wkly Epidemiol Rec. 2022; 97: 493-512. Accessed 12 Nov 2025.

[3] Sun X-J, Zhang G-M, Zhou R-J, et al. Changes in the epidemiology of hepatitis A in three socio-economic regions of China, 1990–2017. Infect Dis Poverty. 2019; 8: 80.

[4] Zhang L. Hepatitis a vaccination. Hum Vaccin Immunother. 2020; 16: 1565-1573.

[5] Foster MA, Hofmeister MG, Kupronis BA, et al. Increase in hepatitis A virus infections – United States, 2013-2018. MMWR Morb Mortal Wkly Rep. 2019; 68: 413-415.

[6] Mcknight KL, Lemon SM. Hepatitis A virus genome organization and replication strategy. Cold Spring Harb Perspect Med. 2018; 8:a033480.

[7] Hirai-Yuki A, Whitmire JK, Joyce M, Tyrrell DL, Lemon SM. Murine models of hepatitis A virus infection. Cold Spring Harb Perspect Med. 2019; 9:a031674.

[8] Lanford RE, Walker CM, Lemon SM. Nonhuman primate models of hepatitis A virus and hepatitis E virus infections. Cold Spring Harb Perspect Med. 2019; 9:a031815.

[9] Sun L, Feng H, Misumi I, et al. Viral protease cleavage of MAVS in genetically modified mice with hepatitis A virus infection. J Hepatol. 2022; 78: 271-280.

[10] Binn LN, Lemon SM, Marchwicki RH, Redfield RR, Gates NL, Bancroft WH. Primary isolation and serial passage of hepatitis A virus strains in primate cell cultures. J Clin Microbiol. 1984; 20: 28-33.

[11] D Ae Mer RJ, Feinstone SM, Gust ID, Purcell RH. Propagation of human hepatitis A virus in African green monkey kidney cell culture: primary isolation and serial passage. Infect Immun. 1981; 32: 388.

[12] Mathiesen LR, Drucker J, Lorenz D, Wagner JA, Gerety RJ, Purcell RH. Localization of hepatitis A antigen in marmoset organs during acute infection with hepatitis A virus. J Infect Dis. 1978; 138: 369-377.

[13] Schulman AN, Dienstag JL, Jackson DR, et al. Hepatitis A antigen particles in liver, bile, and stool of chimpanzees. J Infect Dis. 1976; 134: 80-84.

[14] Purcell RH, Wong DC, Shapiro M. Relative infectivity of hepatitis A virus by the oral and intravenous routes in 2 species of nonhuman primates. J Infect Dis. 2002; 185: 1668-1671.

[15] Dienstag JL, Feinstone SM, Purcell RH, et al. Experimental infection of chimpanzees with hepatitis A virus. J Infect Dis. 1975; 132: 532-545.

[16] Hirai-Yuki A, Hensley L, McGivern DR, et al. MAVS-dependent host species range and pathogenicity of human hepatitis A virus. Science. 2016; 353: 1541-1545.

[17] Li J, Jiang P-Y, Yan X-L, et al. An engineered human hepatitis A virus capable of rapid proliferation in vitro and causing hepatitis in mice. JHEP Rep. 2025; 7:101582.

[18] Liu T, Li J, Yin X, et al. Establishment of enterically transmitted hepatitis virus animal models using lipid nanoparticle-based full-length viral genome RNA delivery system. Gut. 2025; 74: 467-476.

[19] Das A, Hirai-Yuki A, González-López O, et al. TIM1 (HAVCR1) is not essential for cellular entry of either quasi-enveloped or naked hepatitis A virions. MBio. 2017; 8:e00969-17.

[20] Colasanti O, Burm R, Huang HE, et al. Comparison of HAV and HCV infections in vivo and in vitro reveals distinct patterns of innate immune evasion and activation. J Hepatol. 2023; 79: 645-656.

[21] Sun L, Li Y, Misumi I, et al. IRF3-mediated pathogenicity in a murine model of human hepatitis A. PLoS Pathog. 2021; 17:e1009960.

[22] Misumi I, Mitchell JE, Lund MM, Cullen JM, Lemon SM, Whitmire JK. T cells protect against hepatitis A virus infection and limit infection-induced liver injury. J Hepatol. 2021; 75: 1323-1334.

[23] Tsuge M, Hiraga N, Takaishi H, et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology. 2005; 42: 1046-1054.

[24] Meuleman P, Leroux-Roels G. The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV. Antivir Res. 2008; 80: 231-238.

[25] Dandri M, Burda MR, Gocht A, et al. Woodchuck hepatocytes remain permissive for hepadnavirus infection and mouse liver repopulation after cryopreservation. Hepatology. 2001; 34: 824-833.

[26] Pang D. To HAV or Not to HAV: Novel Hepatitis A Virus (HAV) Infection in a Chimeric Mouse Model. 2013. Dissertation. University of Alberta.

[27] Lanford RE, Feng Z, Chavez D, et al. Acute hepatitis A virus infection is associated with a limited type I interferon response and persistence of intrahepatic viral RNA. Proc Natl Acad Sci. 2011; 108: 11223-11228.

[28] Cabanes-Creus M, Navarro RG, Liao SHY, et al. Characterization of the humanized FRG mouse model and development of an AAV-LK03 variant with improved liver lobular biodistribution. Mol Ther Methods Clin Dev. 2023; 28: 220-237.

[29] Hasegawa M, Kawai K, Mitsui T, et al. The reconstituted ‘humanized liver’ in TK-NOG mice is mature and functional. Biochem Biophys Res Commun. 2011; 405: 405-410.

[30] Zhang X, Lu L, Xiao W, Song Y. Humanized liver mouse models in preclinical drug development: current status, translation challenges and emerging technologies. Drug Discov Today. 2026; 31:104611.

[31] Yang Y, Liang Y, Qu L, et al. Disruption of innate immunity due to mitochondrial targeting of a picornaviral protease precursor. Proc Natl Acad Sci USA. 2007; 104: 7253-7258.

[32] Shiota T, Matsuda M, Zheng X, et al. Macrophage depletion reactivates fecal virus shedding following resolution of acute hepatitis A in Ifnar1(−/−) mice. J Virol. 2022; 96:e0149622.

[33] Emerson SU, McRill C, Rosenblum B, Feinstone S, Purcell RH. Mutations responsible for adaptation of hepatitis A virus to efficient growth in cell culture. J Virol. 1991; 65: 4882-4886.

[34] Emerson SU, Huang YK, McRill C, Lewis M, Purcell RH. Mutations in both the 2B and 2C genes of hepatitis A virus are involved in adaptation to growth in cell culture. J Virol. 1992; 66: 650-654.

[35] Liu T, Li J, Yin X, et al. Establishment of enterically transmitted hepatitis virus animal models using lipid nanoparticle-based full-length viral genome RNA delivery system. Gut. 2024; 80: S748.

[36] LeDuc JW, Lemon SM, Keenan CM, Graham RR, Marchwicki RH, Binn LN. Experimental infection of the New World owl monkey (Aotus trivirgatus) with hepatitis A virus. Infect Immun. 1983; 40: 766-772.

[37] Li Y, Misumi I, Shiota T, et al. The ZCCHC14/TENT4 complex is required for hepatitis A virus RNA synthesis. Proc Natl Acad Sci USA. 2022; 119:e2204511119.

Rights & permissions

2026 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.